Hitachi Chemical to acquire apceth Biopharma

04-Feb-2019 - apceth Biopharma GmbH announces that Hitachi Chemical Co., Ltd. will enter into an agreement to acquire all shares of apceth Biopharma GmbH. This acquisition is expected to close in April 2019. Founded 2007, apceth is a pioneer in cell and gene therapy and has developed into a leading European ...

apceth Names Ulrike Verzetnitsch as Chief Technical Office

28-Apr-2015 - apceth GmbH & Co. KG is continuing to expand its senior management team and has announced the appointment of Ulrike Verzetnitsch as Chief Technical Officer with immediate effect.In this newly created role, Ulrike Verzetnitsch will add considerable value to the company by leading apceth’s ...

apceth Initiates Phase II Clinical Trial for Engineered Cell Therapy to Treat Gastrointestinal Cancer

30-Mar-2015 - apceth announced the successful completion of the Phase I and initiation of the Phase II part of its ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, at the Klinikum Grosshadern in Munich. To the company’s knowledge, this is ...

apceth and Indivumed to Develop Biomarker Platform for Targeted Cellular Therapies

24-Feb-2012 - apceth GmbH & Co. KG and Indivumed GmbH have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics. The goal is to predict the response of a targeted cellular / gene therapy in ...

apceth Received Extended Manufacturer's Licence for Somatic Cell Therapeutics At The Ottobrunn Site

04-Nov-2011 - Adult stem cell research at the highest level will be possible at the new apceth site in Ottobrunn near Munich, Germany: in August 2011, the Munich biotech company was granted a manufacturer's licence pursuant to Section 13, German Medicines Act, for the production of somatic cell therapeutics at ...

apceth is extending its top management

Prof. Ralf Huss moves from Roche to the biotechnology company apceth

12-Oct-2011 - On October 1st, Prof. Ralf Huss, previously Global Head of the Therapeutic Cell Initiative at Roche, joined the management board of apceth GmbH & Co. KG, Munich. Ralf Huss will focus on the pre-clinical and early development of cell-based therapeutics and external innovation in the company that ...

apceth Starts First Phase I/II Clinical Study on Somatic Cell Therapy for Peripheral Arterial Occlusive Disease

30 patients involved in the study: initial results expected by mid 2012

24-Aug-2011 - The Munich biotech company apceth started its first phase I/II clinical study on somatic cell therapy for advanced peripheral arterial occlusive disease (pAOD) after angioplasty.The aim is to investigate the tolerability and efficacy of somatic cell therapeutics developed by apceth for the ...

apceth is Granted a Manufacturer's Licence for Somatic Cell Therapy

New manufacturing capacity established in Ottobrunn near Munich

12-Aug-2011 - apceth is among the first companies in Germany to be granted a manufacturer's licence for the production of somatic cell therapeutics pursuant to Section 13, German Medicines Act. "Our aim is to develop innovative cell therapeutics and to close the gap between research and clinical application. ...